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Abstract: 
Hemodialysis is an important alternative for renal replacement therapy to remove uremic 
retention solutes (URS) for the uremic syndrome. The metabolites in the hemodialysate directly 
reflect the efficiency of URS clearance. Here we report a highly sensitive and reliable 
metabolomic procedure for the measurement of small molecule metabolites in hemodialysate 
using gas chromatography coupled with time-of-flight mass spectrometry (GC/TOF/MS). The 
method was developed and evaluated through orthogonal experimental design using multivariate 
statistical analysis. The optimized method involves the use of methanol and water in the ratio of 
3:1 (v/v) for dissolving the lyophilized solid of the hemodialysate after degradation of urea with 
urease (no less than 50 U) for 10 min. Validation of the method demonstrated a good linearity 
with regression coefficients greater than 0.99. Relative standard deviations of precision and 
stability of proposed method were less than 15%, and recoveries ranged from 71.8 to 115.8%. 
This method was successfully applied in the metabolite profiling of human hemodialysate 
samples which was able to differentiate the patients treated with high-flux hemodialysis from 
those with low-flux hemodialysis. The metabolomic results reveal a higher concentration of 
URS, and thus, better URS removal, from the patients under high-flux dialysis than those under 
low-flux dialysis. 
 
Article: 
INTRODUCTION 
Hemodialysis is frequently used in patients with uremia or chronic kidney disease to remove 
uremic retention solutes (URS) from their blood circulation [1,2], as an alternative for renal 
replacement therapy. Over 100 URS have been identified to be involved in uremic syndrome [3-
6]. The blood concentrations of the URS have been extensively investigated [7], partially owing 
to the poor availability of urine samples in end-stage renal diseases (ESRD) [8]. Additionally, the 
accumulation of p-cresol or indole sulfate in patients is believed to be involved in the 
development of cardiovascular diseases, which generally occurs in the late stages of chronic 
kidney diseases due to renal failure [9-11]. Therefore, the URS profile in blood samples directly 
reflects the treatment effect and adequacy of hemodialysis. Gas chromatography coupled with 
mass spectrometry (GC/MS), high-pressure liquid chromatography, liquid chromatography 
coupled with electrospray ionization (LC/ESI/MS), or LC tandem mass techniques have been 
previously applied for the measurement of URS in the blood [12-5]. Hemodialysate contains 
considerable metabolites, which are similar to the blood compositions. Previous studies also 
suggested that the hemodialysate is a biofluid sample more suitable for rapid analytical 
measurement than other biomatrices such as blood or tissue, due to the absence of large proteins 
[16]. Previous approaches for hemodialysate analysis focused only on a few URS at one time, 
which were not able to address global metabolite changes resulting from hemodialysis. It was not 
until recently that an LC/MS-based metabolomics approach was used for the analysis of uremic 
toxins for chronic renal failure rats [14]. Metabolite profiling of hemodialysate by a 
metabolomics approach, such as GC time-of-flight MS (GC/TOF/MS), has not been reported so 
far. In this study, the protocol for measuring the hemodialysate by GC/TOF/MS metabolomics 
approach coupled with multivariate statistical analysis has been firstly developed. The protocol 
was applied in the analysis of hemodialysate samples from human subjects under treatment with 
either high-flux or low-flux hemodialysis. 
 
MATERIALS AND METHODS 
Reagents and materials 
Standard compounds, including methoxyamine, l-2-chlorophenylalanine, heptadecanoic acid, 
and 21 reference standards: 2-aminobutyric acid, isoleucine, leucine, lysine, proline, threonine, 
tryptophan, valine, 3-hydroxybutyric acid, citric acid, malic acid, pyruvic acid, hippuric acid, 
indole-3-acetic acid, arabitol, glycerol, threitol, myo-inositol, sorbitol, hexadecanoic acid and 
oleic acid used for this study were obtained from Sigma–Aldrich (St. Louis, MO, USA). 
Ultrapure water generated from the Milli-Q system (Millipore, USA) was used in the 
experiments. Methanol, acetonitrile, acetone and pyridine were of chromatographic grade and 
purchased from Merck Chemicals (Germany). Anhydrous sodium sulfate (analytical grade) was 
purchased from China National Pharmaceutical Group Corporation (Shanghai, China). N,O-bis-
trimethylsilyl-trifluoroacetamide (BSTFA) + 1% trimethylchlorosilane (TMCS) was purchased 
from Sigma–Aldrich (St. Louis, MO, USA). 
 
Hemodialysate samples 
The study plan including protocols for specimen collection and analyses was approved by the 
local Ethics Committee and informed consent was obtained from all participants prior to the 
study. 60 patients under hemodialysis at a stable physiological condition were recruited in this 
study. 30 patients received hemodialysis with a high flux dialyzer (Fx60, 1.4 m2, polysulfone-
PVP, Helixone®, Fresenius AG, Bad Homburg, Germany) and 30 patients with low flux dialyzer 
(REXEED13L, 1.3 m2, olysulfone-PVP, REXBRANETM, ASAHIKASEI KURARAY medical 
Co. Ltd., Japan). The two dialyzers were operated with a 4008S machine (Fresenius, Fresenius 
Medical Care, Germany). The hemodialysis treatment was performed either three times per week 
for 4 h or 2 times per week for 5 h at the Blood Purification Center of Renji Hospital, affiliated 
to Shanghai Jiao Tong University. The ratio of the patients who received three times to those 
who received two times per week was 13–17 under high-flux dialysis, and 17–13 under low-flux 
dialysis. Heparin sodium was used as anticoagulant during the treatment. An aliquot of 20 ml of 
waste hemodialysates used in the study was collected at the first hour of the dialysis (also the 
first time) of every week using a high-flux or low-flux dialyzer, through a T-pipe equipment 
which is modified from a method reported before [17,18], and immediately stored at −80 °C. 
Pooled samples were prepared by mixing aliquots of the hemodialysate samples (4.5 ml each) 
collected in the study. 
 
Extraction procedure 
The use of urease. Hemodialysate contains a high level of urea, which generates a wide peak 
that often masks the adjacent peaks of other metabolites in total ion chromatograms (TIC) (Fig. 
1A). In order to visualize the adjacent peaks in the chromatogram, the urea peak requires 
attenuation by urease degradation. The amount of urease (0, 50, 100, 150, 200 U) and reaction 
time (10, 20, 30, 40, 50 min) at 37 °C in 2 ml hemodialysate were extensively investigated 
according to an orthogonal experimental design, resulting in a total of 25 conditions (Table S1). 
A series of experiments were performed to evaluate the effect on the peak area of urea in the 
chromatograms. 
 
 
 
Figure 1: A representative TIC of a hemodialysate sample showing the peak of urea (A) before and (B) after 
incubation with urease. Hydrolysis with 50 U urease for 10 min at 37 °C efficiently attenuated the broad urea peak, 
which obscured adjacent metabolites peaks. 
 
 
Selection of solvents for reconstitution. After the incubation with urease at 37 °C, a 2 ml 
aliquot of the pooled hemodialysate sample was placed in a screw-top plastic tube, and 
lyophilized at −80 °C for 4 h. The lyophilized dry sample was reconstituted in different solvents 
for subsequent GC/TOF/MS analysis. The four solvents, methanol, ethanol, acetonitrile and 
water, were compared for their extraction efficiency of metabolites in the lyophilized sample 
with different proportions at a total volume of 500 μl (Table 1). The volume of each solvent 
varied from 0 to 500 μl. Each of the 19 conditions designed in the study was evaluated in 
triplicates. 
 
Table 1: Experimental design for the investigation of the extraction efficiency of different 
solvents. 
No. Run ordera Solvent (μl)b 
  Water Methanol Acetonitrile Acetone Peak numbers 
N1 14,20,52 500 0 0 0 650 
N2 11,36,53 0 500 0 0 619 
N3 3,37,54 0 0 500 0 223 
N4 12,38,57 0 0 0 500 242 
N5 17,23,39 250 250 0 0 660 
N6 19,30,55 250 0 250 0 656 
N7 4,25,56 250 0 0 250 572 
N8 8,29,40 0 250 250 0 661 
N9 9,24,49 0 250 0 250 512 
N10 16,27,41 0 0 250 250 212 
N11 15,31,47 167 167 167 0 586 
N12 18,21,51 167 167 0 167 675 
N13 5,33,42 167 0 167 167 644 
N14 10,28,50 0 167 167 167 557 
N15 13,32,45 125 125 125 125 655 
N16 7,35,48 313 63 63 63 645 
N17 6,22,43 63 313 63 63 668 
N18 2,26,46 63 63 313 63 573 
N19 1,34,44 63 63 63 313 573 
aEach experiment and derivatization was carried out in triplicate prior to analysis by GC/TOF/MS, which was randomized. 
bThe total solvent volume for each experiment was fixed at 500 μl. 
 
 
The effect of ultrasonication on the extraction efficiency of metabolites under 40 Hz from the 
freeze-dried hemodialysate was also investigated. Temperature and duration were evaluated, 
resulting in eight conditions (Table S2), and each condition was repeated in triplicates. 
 
Trimethylsilane (TMS) derivatization procedure 
After vortexing for 30 s, the reconstituted sample was centrifuged at 664 × g for 10 min. An 
aliquot of 300 μl of the supernatant was transferred to a GC vial, to which two internal standards 
(IS) used to evaluate batch reproducibility were added: 10 μl l-2-chlorophenylalanine at 
0.3 mg/ml with working concentration of 9.4 μg/ml and 10 μl heptadecanoic acid at 1.0 mg/ml 
with working concentration of 31.3 μg/ml, which were both within standard linear calibration 
range from 0.15 to 150 μg/ml. Then the supernatant was dried in a vacuum centrifuge 
concentrator prior to the derivatization. The derivatization procedure was conducted with minor 
modifications to our previously published method [19]. Briefly, 80 μl of methoxyamine (at a 
concentration of 15 mg/ml in pyridine, dried with anhydrous sodium sulfate) was added to the 
sample vials containing the dried supernatant and vortexed for 30 s. Methoxymation was carried 
out at 30 °C for 1.5 h. The resultant methoxymation product was then silylated using 80 μl 
BSTFA (containing 1% TMCS) at 70 °C for 1 h followed by mixing for 30 s. The obtained 
derivatized samples were allowed to stand for 1 h at room temperature prior to injection into the 
GC/TOF/MS analysis with controlled room humidity less than 35%. 
 
 
Method validation 
21 standard compounds which resemble main chemical classes and the retention times of the test 
metabolites in the hemodialysate including amino acids, organic acids and fatty acids, were 
chosen for method validation. The linearity of these 21 standard compounds in concentrations 
ranging from 0.15 to 150 μg/ml was evaluated. These standards were prepared from 150 μg/ml 
stock solutions by dilution with water or methanol, at dilution factors of 0.001, 0.002, 0.005, 
0.010, 0.020, 0.050, 0.100, 0.200, 0.500 and 1.000. The limits of detection (LOD) were 
measured as the lowest concentrations of every standard with a signal-to-noise (S/N) ratio of 3. 
The limits of quantification (LOQ) were calculated as the concentrations with S/N ratio of 10. 
The analytical reproducibility was evaluated as relative standard deviation (R.S.D.) from 21 
standard compounds at a concentration of 7.5 μg/ml and the pooled dialysis sample respectively, 
with six replicates for each sample. The stability of the metabolites identified was estimated by 
analyzing the same derivatized hemodialysate samples at intervals 0, 6, 12, 24, 36, 48 h, 
respectively. The recoveries of standard compounds were evaluated by spiking 15 μl of the 21 
standard compounds water/methanol solutions at three different concentrations (75, 150, 
300 μg/ml) to 2 ml hemodialysates, triplicates for each concentration. Then the hemodialysates 
were degraded with urease at 37 °C, the resultant solutions were lyophilized at −80 °C for 4 h. 
The lyophilized solid was dissolved with 500 μl optimized solvent. 300 μl of the dissolution for 
subsequent derivatization was added to two IS before dried in a vacuum centrifuge concentrator. 
The dried samples were derivatized with TMS which were treated as detailed in Section 2.4 prior 
to GC/TOF/MS analysis. 
 
GC/TOF/MS instrumentation 
An aliquot of 1 μl of the derivatized sample was injected into an Agilent 6890N gas 
chromatograph via an Agilent 7683 autosampler using the splitless mode. The injector 
temperature was 270 °C. Separation was achieved on a DB-5 MS capillary column 
(30 m × 250 μm i.d., 0.25 μm film thickness; Agilent J&W Scientific, Folsom, CA, USA) using 
helium as the carrier gas, at a constant flow rate of 1.0 ml/min. The column temperature was held 
at 80 °C for 2 min, and then increased to 180 °C by 10 °C/min, held 0 min, to 230 °C by 
6 °C/min, follow by 40 °C/min to 295 °C and held for 8 min. The Pegasus HT time-of-flight 
mass spectrometer (Pegasus HT, Leco Co., CA, USA) was used. Transfer line and ion source 
temperatures were set at 270 °C and 220 °C, respectively. The mass spectra were obtained with 
electron impact ionization (70 eV) at full scan mode (m/z 30–600), and 20 spectra/s were 
recorded. 
 
Data analysis 
Acquired data files were converted to CDF format by ChromaTOF software (v3.34, Leco Co., 
CA, USA) and then processed by using custom scripts (toolbox HDA, developed by Jonsson et 
al. [20,21]) in MATLAB 7.0 (The Math Works Inc., USA). Data pretreatment procedures such as 
baseline correction, de-noising, smoothing, alignment, time-window splitting, and peak feature 
extraction were carried out sequentially [21]. The peaks which only existed in a small amount of 
samples (<20% samples) were excluded in this procedure. The resulting peak intensity data set 
comprised retention time, sample names, and fragment information. After normalization to the 
areas of internal standards, some false peaks caused by noise, column bleed and derivatization 
procedure, which almost exits in every sample, were removed from the data set. Followed by 
mean centering and unit variance scaling, the resulting data was introduced into the Simca-P 11.5 
software (Umetrics, Umeå, Sweden) for further statistical analysis such as principal components 
analysis (PCA), partial least squares (PLS) regression and/or orthogonal projection to latent 
structures (OPLS) in order to visually display the correlation between the experimental 
parameters and metabolic information. The following statistical models are used throughout this 
article. R2X is the cumulative modelled variation in the X matrix; R2Y is the cumulative modelled 
variation in the Y matrix; and Q2Y is the cumulative predicted variation in the Y variable or 
matrix, according to a sevenfold cross-validation. The range of these parameters is 0-1, where 1 
indicates a perfect fit. Meanwhile, all the metabolites were identified by comparing their mass 
spectra with NIST 05 Standard Mass Spectral Databases in NIST MS search 2.0 (NIST, 
Gaithersburg, MD) software and in-housed library when the similarities were more than 85%. 
About 2/3 of identified metabolites were further confirmed by our reference standards. 
 
RESULTS AND DISCUSSION 
Optimization of the extraction procedure 
We found that 10 min incubation with urease at an amount of greater than 50 U in 2 ml 
hemodialysate did efficiently minimize the urea peak in the full scan TIC (Fig. S1). As a result, 
the peaks of leucine, glycerol and benzoic acid were “uncovered” in the TIC spectrum (Fig. 1B). 
Thus, incubation with 50 U of urease was selected as the preferred method for hydrolysis. 
 
After GC/TOF/MS analysis and data preprocessing, 258 peaks were obtained in over 90% of the 
experiments and 59 of them were annotated based on the NIST database. Regarding the different 
solvent conditions for water and/or methanol, the numbers of peaks ranged from 512 to 707, 
significantly more than those (212–294 peaks) resulted from the acetonitrile and/or acetone 
solvents. Therefore, the performance of water and methanol seemed to be superior to the other 
two solvents. A two-component PLS model was generated based on the resolved peak areas 
(matrix X) and the solvents used in the experiment (matrix Y). The R2X, R2Y and Q2 parameters 
of the model are 0.667, 0.325 and 0.271, respectively. In Fig. 2A, solvent systems N3, N4, N8, 
N9, N10, N14, N18 and N19, using acetone and acetonitrile as solvents, are located in the lower 
left quadrant based on their relative lower peak intensities. In contrast, solvent systems N1, N5, 
and N16 yielded higher peak intensities since they are located in the upper right quadrant of the 
plot. In terms of extraction efficiency and peak intensity, water and methanol seemed to be better 
than acetone and acetonitrile. The PLS loading plot (Fig. 2B) showed that the majority of the 
resolved peaks were strongly correlated with methanol and water. Only a few peaks were 
efficiently extracted by acetonitrile and acetone. This result implied that a solvent system 
containing water and methanol was most suitable for maximum peak number and intensity. 
 
 
Figure 2: PLS model (four components, R2X = 0.725, R2Y = 0.565, Q2Y = 0.44) of optional solvents for extraction 
procedure. (A) The PLS scores plot (t1 − u1) shows the correlation between the X matrix (the peak areas of the 
resolved metabolite peaks) and the Y matrix (the different solvent systems; dots labeled according to Table 1, such 
as 4_1 i.e. solvent system no. 4, replicate no. 1). The lower left quadrant of the plot describes solvent conditions that 
produced the lowest overall peak areas, while the upper right quadrant describes those that yielded the best results in 
terms of peak areas. (B) The PLS loading plot summarizes the influence and correlation between the X matrix (▴, the 
areas of the resolved GC/TOF/MS peaks) and the Y matrix (■, the different solvents). Methanol and water were 
strongly correlated with a majority of the resolved peak areas. 
 
 
An experiment was designed to optimize the methanol to water ratio in the solvent system, in 
which each condition was repeated in triplicates (Table S3). A total of 520 peaks were detected 
and 68 of which were annotated. We used 68 known metabolites and the 15 solvent conditions to 
construct a three-component PLS model, which yielded good model parameters, R2X = 0.802, 
R2Y = 0.983, and Q2 = 0.949; we also used 520 peaks as variables to construct another three-
component PLS model, which also yielded good parameters, R2X = 0.472, R2Y = 0.986, 
Q2 = 0.652. The modelling results from the two sets of variables were similar to each other (see 
Fig. S2). The t1 vs. u1 plot (Fig. 3A) showed that solvent systems 4 and 5 resulted in the highest 
overall peak areas. The bi-plot (Fig. 3B) showed that a higher ratio of methanol was preferable 
for hydrophobic compounds, but less so for hydrophilic compounds. The result suggested that an 
acceptable compromise in extraction efficiency between polar and non-polar metabolites could 
be reached at a 3:1 ratio of methanol/water (experiment 4). 
 
 
Figure 3: PLS model (three components, R2X = 0.802, R2Y = 0.983, Q2 = 0.949) of the ratio of methanol and water 
for extraction procedure. (A) The PLS scores plot (t1 − u1) shows the correlation between the X matrix (the peak 
areas of the resolved identified metabolites) and the Y matrix (the solvent conditions, as in Table S2, such as 5_1 i.e. 
solvent system no. 5, replicate no. 1). The upper right quadrant shows the experimental conditions that yielded the 
highest overall peak areas. (B) The PLS bi-plot shows the correlation between the peak areas of 68 endogenous 
metabolites and the experimental conditions (black triangles, identified metabolites; red squares, methanol and 
water; blue squares, different methanol: water compositions, with labeling according to Table S2). Solvent 
composition 4, i.e. the mixture of methanol: water (3:1, v/v) was able to extract most of these compounds. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.) 
 
 
Regarding the ultrasonic influence kept at a constant frequency of 40 Hz during reconstitution, 
the metabolites were annotated in line with the NIST database after GC/TOF/MS analysis and 
data processing. The R.S.D.s of most of these metabolites were less than 50%, which suggested 
that the ultrasound procedure did not significantly enhance the extraction efficiency, and 
therefore, was not necessary. 
 
Validation of the optimized method 
Linearity, LODs and LOQs. Each calibration curve was constructed by the ratio of standard 
peak area to IS peak area plotting against nominal standard concentrations. The correlation 
coefficients (r2) for all 21 standard compounds exceeded 0.99, indicating good linearity of the 
method. The LODs and LOQs of standards which showed in pg on column were relatively low 
(Table 2). 
 
 
 
 
 
 
 
Table 2: Linearity, LOD, LOQ, stability, precision and recovery for method validation (n = 6) with 21 standard 
compounds. 
Compounds Linear 
range 
(μg/ml) 
Correlation 
coefficients 
LOD pg 
on 
column 
LOQ pg 
on 
column 
Stability 
(%) 
Precision (%) Recovery (%) 
     Samples Standards Samples Averagea 
2-Aminobutyric acid 0.15–150 0.999 8.4 28.1 11.4 1.0 8.5 79.3 
Isoleucine 0.15–75 0.997 4.2 14.1 9.4 0.9 3.0 82.5 
Leucine 0.15–150 0.999 4.2 14.1 10.3 2.1 3.1 87.5 
Lysine 0.15–75 0.998 16.9 56.3 5.1 1.6 7.7 105.8 
Proline 0.15–150 0.998 8.4 28.1 12.8 1.2 4.9 85.1 
Threonine 0.15–150 0.998 42.3 141.0 8.4 1.6 3.2 92.6 
Tryptophan 0.75–150 0.997 33.8 112.5 8.5 1.9 3.2 109.8 
Valine 0.15–150 0.999 8.4 28.1 13.3 1.6 4.4 87.3 
3-Hydroxybutyric acid 0.15–150 0.994 42.3 141.0 6.5 1.0 5.1 105.3 
Citric acid 7.5–150 0.993 42.3 141.0 3.3 1.9 3.1 74.0 
Malic acid 0.15–150 0.997 8.4 28.1 5.7 2.7 3.9 95.9 
Pyruvic acid 0.15–150 0.995 42.3 141.0 11.5 9.1 2.5 110.1 
Hippuric acid 1.5–150 0.996 42.2 140.5 14.5 7.7 9.9 94.4 
Indole-3-acetic acid 0.15–150 0.998 16.9 56.2 8.0 3.1 3.7 86.2 
Arabitol 0.15–150 0.999 8.4 28.1 5.2 2.0 3.2 102.3 
Glycerol 0.15–75 0.999 4.2 14.1 7.2 0.8 2.5 98.5 
Threitol 0.15–150 0.998 8.4 28.1 5.0 1.1 3.7 101.2 
Myo-inositol 0.15–150 0.997 8.4 28.1 4.6 2.4 3.0 115.8 
Sorbitol 0.15–150 0.997 16.9 56.2 3.1 1.3 3.9 71.8 
Hexadecanoic acid 0.15–150 0.999 8.4 28.1 14.1 3.5 5.6 80.2 
Oleic acid 0.15–150 0.999 84.3 281.0 10.7 3.5 3.2 92.3 
aAverage recovery was obtained by nine samples (three parallel samples at three different concentrations). 
 
 
Precision, stability and recovery. The R.S.D.s of six replicates ranged from 0.8 to 9.1% for 
standards, 2.5–9.9% for pooled hemodialysate samples (Table 2). The results demonstrated high 
repeatability by different individual operator in our laboratory. Additionally, the stability was 
found to be acceptable with R.S.D.s ranging from 3.1 to 14.5% within 48 h at room temperature. 
This result indicates that TMS derivatized samples are chemically stable for at least 48 h, thereby 
allowing a high-throughput GC/TOF/MS analysis of a large sample size. The recovery of the 
proposed method ranged from 71.8% to 115.8% for the 21 standard compounds, demonstrating a 
good reliability of the optimized method. 
 
Application 
The method was used to measure the metabolites in hemodialysate samples from 60 patients, 30 
treated with high-flux dialysis and 30 with low-flux dialysis. The GC/TOF/MS data was 
normalized by peak areas of heptadecanoic acid, one of the internal standards, and then analyzed 
by uni- and multi-variate statistical methods. A clear separation was achieved between these two 
groups, indicating significant inter-group metabolic differences. An OPLS model (R2X = 0.269, 
R2Y = 0.93, Q2Y = 0.369; Fig. 4) was constructed to identify the differential metabolites 
contributing to the separation of these two groups. A total of 59 variables with VIP > 1 and 
P < 0.05 (t-test) were selected as markers. A total of 21 of them were annotated by means of 
NIST and 15 were confirmed by our in-house library established using reference standards. The 
VIP scores, significance levels, and fold changes of these metabolite markers are illustrated in 
the bar graph (Fig. 5). It can be readily observed that the concentrations of metabolites from 
high-flux treated patients were higher than the other group, including some uremic toxins such as 
hippuric acid, indole-3-acetic acid and arabitol, in particular. The result suggests that the high-
flux hemodialysis may be advantageous over the low-flux dialysis in removing more uremic 
toxins from the blood stream [22]. 
 
 
 
Figure 4: OPLS scores plot (1P + 3O, R2X = 0.269, R2Y = 0.93, Q2Y = 0.369) of the metabolite profiles from high-
flux treated patients (black squares) and low-flux treated patients (red dots). (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of the article.) 
 
 
 
 
Figure 5: Comparison of 21 metabolites from two different dialysis methods using GC/TOF/MS. Variables with 
VIP > 1 and P value < 0.05 (t-test) were selected as differential signals. A fold change with a positive value 
indicated a relatively higher concentration present in hemodialysate from high-flux treated patients. aMetabolites 
were confirmed by comparison with reference standards, others were directly identified by comparison library 
database. *Highly significant at P < 0.01. 
 
CONCLUSION 
In this study, a new method for profiling the hemodialysate metabolites has been developed 
using GC/TOF/MS. The optimized procedure was concluded as following: 20 μl urease (no less 
than 50 U) was added to 2 ml hemodialysate sample to minimize the influence of the urea before 
lyophilization. A 500 μl aliquot of mixed solvents (methanol:water = 3:1, v/v) was added to 
dissolve the lyophilized solid with the maximum amount of metabolites detected for 
GC/TOF/MS analysis after TMS derivatization. The developed method is sensitive, rapid and 
reproducible. The method was successfully applied to a metabolomic analysis of hemodialysate 
samples from 60 patients who were under high-flux or low-flux dialysis. The results 
demonstrated that the high-flux dialysis resulted in a relative higher concentration of URS in 
hemodialysate samples than the low-flux dialysis. The results also suggest that the high-flux 
dialysis is more beneficial in the removal of uremic toxins from the blood stream. 
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